Non-Small Cell Lung Cancer (NSCLC)

Latest News

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Patritumab Deruxtecan Demonstrates Continued Activity in Breast/Lung Cancer

March 22nd 2023

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.

New findings from the phase 3 ADAURA trial “provide powerful evidence” of osimertinib’s potential to extend the lives of patients with early-stage, EGFR-mutant non–small cell lung cancer, according to an expert from Yale Cancer Center.
Adjuvant Osimertinib Appears to Extend Overall Survival in EGFR+ NSCLC

March 18th 2023

Final analyses for pathologic response appear consistent with previous reports from the phase 3 AEGEAN trial evaluating neoadjuvant durvalumab and chemotherapy plus adjuvant durvalumab monotherapy in resectable non–small cell lung cancer.
Neoadjuvant/Adjuvant Durvalumab Yields Meaningful EFS Benefit in NSCLC

March 9th 2023

The VENTANA PD-L1 Assay becomes the only FDA-approved companion diagnostic with locally advanced or metastatic non–small cell lung cancer indications for 4 immunotherapy agents.
FDA Expands VENTANA PD-L1 Assay Label for Cemiplimab in NSCLC Subtype

March 6th 2023

Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.
Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung Cancer

March 5th 2023

Latest CME Events & Activities

Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

Trekking Through the Latest Updates for ROS1-Targeted Therapies

View More

Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care

View More

Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC

View More

Navigating the Latest Data on NTRK-Targeted Therapies

View More

Community Practice Connections™: 17th Annual New York Lung Cancers Symposium

View More

Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow

View More

Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC

View More

Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care

View More

Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers

View More

Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care

View More

Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC

View More

Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC

View More

Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment

View More

Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer

View More

Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management

View More

Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC

View More

Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target

View More

Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More

Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care

View More

Advances In™: The Role of NRG1 Fusions Across Tumor Types

View More

Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings

View More

Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future

View More

Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!

View More